Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.46 USD
Change Today +0.27 / 6.44%
Volume 298.7K
OCAT On Other Exchanges
As of 1:52 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

ocata therapeutics inc (OCAT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/15/14 - $9.45
52 Week Low
08/14/15 - $3.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ocata therapeutics inc (OCAT) Related Bloomberg News

View More Bloomberg News

ocata therapeutics inc (OCAT) Related Businessweek News

No Related Businessweek News Found

ocata therapeutics inc (OCAT) Details

Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, as well as pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory, and wound healing-related disorders. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company’s intellectual property portfolio also comprises cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of February 11, 2015, it had 58 issued patents and 180 pending patent applications for the development of intellectual property portfolio. The company was formerly known as Advanced Cell Technology Inc. and changed its name to Ocata Therapeutics, Inc. in November 2014. Ocata Therapeutics, Inc. is headquartered in Marlborough, Massachusetts.

37 Employees
Last Reported Date: 03/16/15

ocata therapeutics inc (OCAT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $243.3K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $357.5K
Chief Medical Officer
Total Annual Compensation: $351.9K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $66.0K
Chief Scientific Officer
Total Annual Compensation: $485.1K
Compensation as of Fiscal Year 2014.

ocata therapeutics inc (OCAT) Key Developments

Ocata Therapeutics, Inc. Announces Canine Patients Treated with its Hemangio-Derived Mesenchymal Cells Achieve Remission in Model of Crohn’s Disease

Ocata Therapeutics, Inc. reported in Regenerative Medicine that it has successfully used its proprietary hemangio-derived mesenchymal cell (HMCTM) technology to treat dogs with canine anal furunculosis (CAF), which shares many features with Crohn’s disease.

Ocata Therapeutics, Inc. Enrolls First Patient in Ocata Therapeutics’ Phase 2 Study for Dry AMD

Ocata Therapeutics, Inc. announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared to a parallel control group. Interim top-line results from the first cohort is expected in the second quarter of 2016 and the interim read-out on the second two cohorts is expected by the end of 2016. This Phase 2 study will include up to three cohorts of up to 20 subjects each. Each of the cohorts will receive one week of immune suppressive therapy prior to surgery and then different immune suppression regimens following transplantation of the cells, to determine the safety and tolerability of 0, 6 and 12 weeks of post-transplant systemic immune suppression. Untreated patients will receive placebo treatment similar in appearance and administration to those who have received cellular transplants.

Ocata Therapeutics, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 01:30 PM

Ocata Therapeutics, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 01:30 PM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Paul K. Wotton, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCAT:US $4.46 USD +0.27

OCAT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.49 USD -0.20
Neuralstem Inc $1.31 USD +0.055
Organovo Holdings Inc $2.88 USD +0.1323
ReNeuron Group PLC 4.13 GBp -0.125
StemCells Inc $0.45 USD +0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation OCAT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 970.5x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 918.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCATA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at